
Heterogeneity in Critical Illness: Challenges and Opportunities

Kathryn A. Hibbert, MD
International Summer Institute on Network Physiology
2 August, 2019

47 year old healthy man presents with subjective fever, muscle aches and vague abdominal pain.




Outline

➤ Context and Definitions

- ➤ Syndromes versus Diseases
- ➤ Impact of Heterogeneity
- ➤ Network Physiology Opportunities

Burden of Critical Illness – Incidence (US)




Significant morbidity, mortality, and cost associated with these conditions


Acute Respiratory Distress Syndrome The Berlin Definition

The ARDS Definition Task Force*

	Acute Respiratory Distress Syndrome
Acute	Within 1 week of a known clinical insult or new or worsening respiratory symptoms
Abn'l Imaging	Bilateral opacities—not fully explained by effusions, lobar/lung collapse, or nodules
Not Something Else	Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present
ow Oxygen Levels	200 mm Hg < Pao₂/Fio₂ ≤ 300 mm Hg with PEEP or CPAP ≥5 cm H₂O°
	100 mm Hg < Pao₂/Fio₂ ≤ 200 mm Hg with PEEP ≥5 cm H₂O
	PaO ₂ /FiO ₂ ≤ 100 mm Hg with PEEP ≥5 cm H ₂ O








Ware & Matthay. NEJM 2000

Definition of Sepsis

"Life-threatening organ dysfunction caused by a dysregulated host response to infection"



Cental Nervous System

Acute change or worsening mental status

Respiratory


Tachypnea
Increased need for
O₂

Renal

Decrease urine output
Rising creatinine

Metabolic

Elevated lactate



Cardiovascular

Hypotension

Liver

Elevated bilirubin, AST, ALT, Alk Phos

Circulatory


Poor capillary refill Skin mottling

Hematologic


Thrombocytopenia Coagulopathy (elevated INR, DIC)

Overall Toxic Appearance

Critical Illness as Final Common Pathway?



Critical Illness as Final Common Pathway?




Sepsis and ARDS are *Syndromes*, not Diseases

- ➤ No specific biomarker (e.g. a blood test) to identify either "sepsis" or ARDS
- ➤ Diagnosis can be made at the bedside, but may not be specific (or even that sensitive)
- ➤ Purposefully inclusive definitions based on easily accessible clinical information
- > Developed from need for a case definition




Have we really come that far?

Early Identification -> Early Intervention




Timing of antibiotics in septic shock affects survival

time from hypotension onset (hrs)




Ventilator management at ARDS onset impacts survival

A Challenge of Syndromic Definitions: Heterogeneity!!



- **Subphenotypes:** groups that appear different in some way
- Endotypes: groups with distinct disease processes




Thille AW, et al. AJRCCM 2013

How to Identify Subgroups in ARDS


- What caused it?
 - Direct versus indirect injury

- What does it look like? (anatomic)
 - Focal versus diffuse
- What does it look like? (biomarker profile)
 - Latent class analysis




Calfee CS, et al. Lancet Respir Med 2014


Sepsis Phenotypes




How do we know our subgroups are real?

• Do they behave differently? Prognosis or Therapeutic Response







Some subgroups are identifiable




Some subgroups are not identifiable





And it's probably even worse than we know....


Why Does Heterogeneity Matter?




Nitric Oxide Surfactant/perflourocarbon **Corticosteroids Prostaglandin E1** Lysophyline **Ibuprofen** Procysteine Anticytok ne/antiendotoxin Ketoconazole Streptakinase Neutrophil astase inhibitor sPLA2 inhibitor rhAPC Albuterol/salmeterol **Furosemide** Cisatricurium **GMCSF Beta Agonists Statins**

Alkaline Phosphatase Granulocyte Colony-stimulating Factor nti-tumor Necrosis Factor Ab Recombinant human tissue pathway **Ibuprofen** N-acetylcysteine Nitric Oxide Inhibitors Growth Hormone Bradykinik Antagonists Levosimendan Hypothe mia Hyperoxia Hypertonic saline Hemoper usion through Polymyxin B Interleukin 1 Receptor Antagonist **TLR-4 Antagonsist Anti-Endotoxin Antibody Activated Protein C Recombinant Thrombomodulin**

Why Heterogeneity Matters





Heterogeneity of Treatment Effect

Summary So Far...

Common and Highly Morbid Conditions


→ Importance of Early Recognition and Intervention

Heterogeneous Groups

Need for More Targeted Trials and Therapies


= Opportunity for Network Physiology??

Critical Illness and Network Physiology: Multiorgan Failure




Sepsis is defined by dysfunction of multiple organs and is a systems disease

ARDS (although a "pulmonary" disease) is often part of a cycle of inflammation and organ failure



Critical Illness and Network Physiology: The Data




 Critical illness is a data rich condition...


- Standard of care* is continuous monitoring of multiple organ systems
- Electronic medical record and central storage of monitoring data




Critical Care and Network Physiology



47 year old healthy man presents with subjective fever, muscle aches and vague abdominal pain.





kahibbert@mgh.harvard.edu